Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer

22:31 EDT 9 Jul 2018 | SCRIP

Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half...

More From BioPortfolio on "Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer"